Le Lézard
Classified in: Health
Subjects: TRI, FDA

LaunchPad Medical Received FDA Approval to Initiate a Clinical Study


LOWELL, Mass., Sept. 12, 2019 /PRNewswire/ -- LaunchPad Medical, Inc. has received approval from the U.S. Food and Drug Administration to initiate a two-site, 20-patient pilot clinical study to examine the safety and efficacy of the company's bone adhesive biomaterial (known as Tetranite®) to immediately stabilize dental implants for tooth extractions.

Patients will be enrolled in the study if an extraction site is too large for dental implants to achieve primary stability through conventional mechanical engagement, which is often the case.  Instead, the use of Tetranite will allow for the immediate placement of implants and, in many cases, obviate a costly, complex, and lengthy bone grafting process, greatly accelerating the overall treatment timeframe for many patients.

"We are excited to take the next step in commercializing this promising bone adhesive technology that has the opportunity to improve and significantly accelerate the current treatment paradigm for dental implant procedures," said LaunchPad Medical's Chief Executive Officer, Brian Hess.  "Having also just received investigational review board (IRB) approval, we are ready to start enrolling patients at our clinical sites. This marks a significant milestone since it is the first-in-man trial based on this technology platform."

The unique properties of Tetranite include the ability to provide immediate fixation of fractured bone fragments and stabilization of metal implants to bone.  In multiple animal studies this adhesive has been shown to be a non-toxic and effective way of repairing bone fractures and defects as well as securing implant devices.  Existing data has also shown that Tetranite is resorbed and replaced with new bone during the natural process of bone remodeling by acting as a scaffold to facilitate bone growth.  LaunchPad Medical's Tetranite technology has not yet been approved for commercial use.

About LaunchPad Medical, Inc.

LaunchPad Medical, Inc. is a medical device company engaged in the development and commercialization of a novel injectable, self-setting, and osteoconductive bone adhesive biomaterial called Tetranite®.  The Company's initial focus with this technology is for use in the dental market; however, the company is also working to develop adhesive applications in the broader orthopedics market.  LaunchPad operates out of the Massachusetts Medical Device Development Center (M2D2), an accelerator program for medical devices.

SOURCE LaunchPad Medical, Inc.


These press releases may also interest you

4 jui 2020
SummaryProducts: Cetrotide 0.25mg Issue: One lot of Cetrotide 0.25mg is being recalled because some vials may have missing stoppers, which could make the product unsterile. What to do: Check the lot number on your product or contact your pharmacist...

4 jui 2020
In lieu of an in-person update to the media, Dr. Theresa Tam, Canada's Chief Public Health Officer, issued the following statement today: "There have been 105,091 cases of COVID-19 in Canada, including 8,663 deaths. 65% of people have now recovered....

4 jui 2020
The latest data of the evolution of COVID-19 in Québec reveal 102 new cases over the past 24 hours, bringing the total number of people infected to 55,784. During the same period, 3 new deaths were recorded, to which are added 3 deaths that occurred...

4 jui 2020
On Friday, the British government announced that, as of July 10th, those travelling from the Commonwealth of Dominica to England need not self-isolate for 14 days. Dominica is one of the 59 countries and 14 British Overseas Territories forming a...

4 jui 2020
Gilead Sciences, Inc. today announced data from an ongoing Phase 1 study, which showed that a sustained-delivery subcutaneous formulation of the company's investigational, novel inhibitor of HIV-1 capsid function, lenacapavir (GS-6207), sustained...

4 jui 2020
Gilead Sciences, Inc. today announced data demonstrating the safety and efficacy of the once-daily, single tablet regimen Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) in virologically suppressed...



News published on 12 september 2019 at 13:44 and distributed by: